BIOCYTOGEN PHARMA. H YC1 (I54) — Net Asset Momentum
BIOCYTOGEN PHARMA. H YC1 (I54) recorded a net asset momentum of 159.9% as of December 2025, with net assets of €2.18 Billion EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See BIOCYTOGEN PHARMA. H YC1 liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
BIOCYTOGEN PHARMA. H YC1 Net Asset Momentum (2021–2025)
This chart tracks BIOCYTOGEN PHARMA. H YC1's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +159.9%, with net assets of €2.18 Billion EUR as of December 2025. Read BIOCYTOGEN PHARMA. H YC1 debt and liabilities for a breakdown of total debt and financial obligations.
Annual Net Asset History for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below shows the complete annual net asset history for BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see BIOCYTOGEN PHARMA. H YC1 stock valuation.
| Year | Net Assets (EUR) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | €2.18 Billion | €3.72 Billion | €1.54 Billion | ▲ +159.9% |
| 2024 | €838.60 Million | €2.42 Billion | €1.58 Billion | ▲ +6.1% |
| 2023 | €790.44 Million | €2.45 Billion | €1.66 Billion | ▼ -31.3% |
| 2022 | €1.15 Billion | €2.80 Billion | €1.65 Billion | ▼ -8.1% |
| 2021 | €1.25 Billion | €2.30 Billion | €1.05 Billion | — |